low-field mri system
Bayer to Present Phase III Gadoquatrane Data at ECR 2026
Bayer will present new Phase III clinical data for its investigational low-dose MRI contrast agent gadoquatrane at ECR 2026 in Vienna.
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.
